USE VIMPAT® AS
ADJUNCTIVE THERAPY OR MONOTHERAPY FOR CHILDREN

(4 YEARS OF AGE AND OLDER).

LEARN MORE


The pediatric indication for VIMPAT is based on the principle of extrapolation of efficacy data from adults and is supported by safety and pharmacokinetics data collected in children.

The efficacy of VIMPAT in pediatric patients 4 years of age and older with partial-onset seizures was confirmed in a placebo-controlled pediatric trial.

Adult Efficacy Data

Pediatric Placebo-Controlled Trial

The pediatric indication for VIMPAT is based on the principle of extrapolation of efficacy data from adults and is supported by safety and pharmacokinetics data collected in children.

The efficacy of VIMPAT in pediatric patients 4 years of age and older with partial-onset seizures was confirmed in a placebo-controlled pediatric trial.


INDICATION

VIMPAT® is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of VIMPAT injection in pediatric patients has not been established, VIMPAT injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).

SELECT IMPORTANT SAFETY INFORMATION

VIMPAT is associated with important warnings and precautions including suicidal behavior and ideation, dizziness and ataxia, cardiac rhythm and conduction abnormalities, syncope, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi-organ hypersensitivity.

In the adult monotherapy clinical trial, adverse reactions were generally similar to those observed and attributed to drug in adjunctive placebo-controlled trials, with the exception of insomnia (observed at a higher rate of ≥2%). In the adult adjunctive placebo-controlled trials, the most common adverse reactions (≥10% and greater than placebo) were dizziness, headache, nausea, and diplopia. Pediatric adverse reactions are similar to those seen in adult patients.

VIMPAT is a Schedule V controlled substance.

View full Prescribing Information

VIMPAT IS APPROVED FOR TREATMENT OF PEDIATRIC PATIENTS AGES 4 YEARS AND OLDER BASED ON EXTRAPOLATION OF DATA FROM ADULT STUDIES, INCLUDING:

  • Three 12-week, randomized, multicenter, placebo-controlled, double-blind clinical adjunctive therapy trials in adult patients at 200 mg/day and 400 mg/day3-5
  • A conversion-to-monotherapy trial in adult patients using a historical control group8


VIMPAT pediatric efficacy also was studied in a placebo-controlled adjunctive trial that demonstrated efficacy in pediatric patients 4 years of age and older with partial-onset seizures with or without secondary generalization.1

Adult efficacy dataPediatric placebo-controlled trial

ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS (4 years of age and older)

VIMPAT ESTABLISHED ADULT EFFICACY HAS
BEEN EXTRAPOLATED FOR PEDIATRIC PATIENTS.2

Adult efficacy was demonstrated in patients with partial-onset seizures and has been extrapolated to children ages 4 and older according to FDA guidelines.

ADULT ADJUNCTIVE EFFICACY

VIMPAT demonstrated significant control of partial-onset seizures in adults with or without secondary generalization.

  • The efficacy of VIMPAT as adjunctive therapy was established in three 12-week, randomized, multicenter, placebo-controlled, double-blind clinical trials at 200 mg/day and 400 mg/day


≥50% RESPONDER RATES FROM BASELINE WITH VIMPAT VS PLACEBO IN PIVOTAL ADJUNCTIVE THERAPY ADULT TRIALS3-5*
VIMPAT® (lacosamide) CV ≥50% Responder Rates From Baseline vs Placebo Chart
VIMPAT® (lacosamide) CV ≥50% Responder Rates From Baseline vs Placebo Chart VIMPAT® (lacosamide) CV ≥50% Responder Rates From Baseline vs Placebo Chart VIMPAT® (lacosamide) CV ≥50% Responder Rates From Baseline vs Placebo Chart
  • Significantly more VIMPAT patients demonstrated a 50% or greater reduction in seizures compared with placebo3-5
  • In adult adjunctive placebo-controlled trials (200 mg/day and 400 mg/day), the most common adverse reactions (≥10% and greater than placebo) were dizziness, headache, nausea, and diplopia2

Learn more about adult efficacy data

MONOTHERAPY IN PEDIATRIC PATIENTS (4 years of age and older)

FOR MONOTHERAPY, VIMPAT MET THE PREDEFINED CRITERIA
FOR EFFICACY IN ADULTS WITH PARTIAL-ONSET SEIZURES.2,8

VIMPAT USE AS MONOTHERAPY IN ADULTS WITH PARTIAL-ONSET SEIZURES WAS EVALUATED IN A HISTORICAL CONTROL TRIAL

VIMPAT was tested in a conversion-to-monotherapy trial using a historical control group derived from a meta-analysis of data from 8 previous AED monotherapy trials of similar design, which utilized a subtherapeutic dose of an AED as a control.

  • VIMPAT met the pre-specified criteria for efficacy at doses of 400 mg/day or 300 mg/day
  • VIMPAT demonstrated statistical superiority to the historical control
  • In the adult monotherapy clinical trial (300 mg/day and 400 mg/day), adverse reactions were generally similar to those observed and attributed to drug in adult adjunctive placebo-controlled trials, with the exception of insomnia (occurred at a higher rate of ≥2%)

Pediatric Efficacy

VIMPAT PEDIATRIC EFFICACY WAS STUDIED IN A
PLACEBO-CONTROLLED ADJUNCTIVE TRIAL.1

The efficacy and safety of adjunctive VIMPAT therapy in 343 pediatric patients 4 years of age and older with partial-onset seizures not adequately controlled by 1 to 3 concomitant AEDs was further established in a 10-week, placebo-controlled, double-blind, multicenter, randomized trial.

POOLED BASELINE DEMOGRAPHICS AND CHARACTERISTICS
VIMPAT® (lacosamide) CV Pooled Baseline Demographics and Characteristics Table
VIMPAT® (lacosamide) CV Pooled Baseline Demographics and Characteristics Table

*AEDs taken and stopped >28 days prior to entering baseline period or AEDs with unknown stop date.

VIMPAT PEDIATRIC EFFICACY WAS CONFIRMED IN PATIENTS WITH PARTIAL-ONSET SEIZURES.1

Pediatric adjunctive efficacy

VIMPAT demonstrated efficacy in pediatric patients with partial-onset seizures with or without secondary generalization.

≥50% RESPONDER RATES FROM BASELINE TO MAINTENANCE PERIOD WITH VIMPAT VS
PLACEBO IN PEDIATRIC, PLACEBO-CONTROLLED ADJUNCTIVE THERAPY TRIAL
VIMPAT® (lacosamide) CV ≥50% Response, Baseline to Maintenance vs Placebo Chart

Average median VIMPAT total daily dose during maintenance period

|  <30 kg: 10.5 mg/kg/day  |  ≥30 to <50 kg: 7.4 mg/kg/day  |  ≥50 kg: 6.2 mg/kg/day  |

  • Significantly more VIMPAT pediatric patients demonstrated a 50% or greater reduction in seizures compared to patients taking placebo
    • FDA approval was based on the adult efficacy data
  • In the pediatric placebo-controlled trial, the most common adverse reactions (≥10%) were dizziness and somnolence

References

  1. 1.Data on file. UCB, Inc.
  2. 2.VIMPAT® (lacosamide): US prescribing information. Smyrna (GA): UCB, Inc., November 2017.
  3. 3.Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308-1317.
  4. 4.Chung S, Sperling MR, Biton V, et al; on behalf of the SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51(6):958-967.
  5. 5.Halász P, Kälviäinen R, Mazurkiewicz-Bełdzińska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50(3):443-453.
  6. 8.French JA, Wang S, Warnock B, et al. Historical control monotherapy design in the treatment of epilepsy. Epilepsia. 2010;51(10):1936-1943.

Important Safety Information

Warnings and Precautions

  • Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including VIMPAT, increase the risk of suicidal behavior and ideation. Monitor patients taking VIMPAT for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients and caregivers to be alert for these behavioral changes and to immediately report them to the healthcare provider.

  • Dizziness and Ataxia: VIMPAT may cause dizziness and ataxia. In adult clinical trials, the onset of dizziness and ataxia was most commonly observed during titration. Advise patients not to drive, operate complex machinery, or engage in other hazardous activities until they are familiar with the effects of VIMPAT on their ability to perform such activities. Dizziness and ataxia were also observed in pediatric clinical trials.

  • Cardiac Rhythm and Conduction Abnormalities:

    PR interval prolongation

    Dose-dependent prolongations in PR interval with VIMPAT have been observed in clinical studies in adult patients and in healthy volunteers. Second-degree and complete AV block have been reported in patients with seizures. When VIMPAT is given with other drugs that prolong the PR interval, further PR prolongation is possible.

    Use VIMPAT with caution in patients with known cardiac conduction problems (e.g., marked first-degree AV block, second-degree or higher AV block and sick sinus syndrome without pacemaker), sodium channelopathies (e.g., Brugada Syndrome), or with severe cardiac disease such as myocardial ischemia or heart failure, or structural heart disease. Also, use VIMPAT with caution in patients on concomitant medications that prolong PR interval (e.g., beta-blockers and calcium channel blockers) because of a risk of AV block or bradycardia. In such patients, obtaining an ECG before beginning VIMPAT, and after VIMPAT is titrated to steady-state maintenance dose, is recommended. In addition, closely monitor these patients if they are administered VIMPAT through the intravenous route.

    Atrial fibrillation and Atrial flutter

    VIMPAT administration may predispose to atrial arrhythmias (atrial fibrillation or flutter), especially in patients with diabetic neuropathy and/or cardiovascular disease.

  • Syncope: VIMPAT may cause syncope in adult and pediatric patients.

  • Withdrawal of Antiepileptic Drugs: Gradually withdraw VIMPAT (over a minimum of 1 week) to minimize the potential of increased seizure frequency.

  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as multi-organ hypersensitivity, has been reported with antiepileptic drugs. Some of these events have been fatal or life-threatening. If signs or symptoms are present, immediately evaluate the patient. Discontinue VIMPAT if an alternative etiology for the signs and symptoms cannot be established.

  • Risks in Patients with Phenylketonuria: VIMPAT oral solution contains aspartame, a source of phenylalanine which can be harmful in patients with phenylketonuria (PKU). A 200 mg dose of VIMPAT oral solution (equivalent to 20 mL) contains 0.32 mg of phenylalanine.

Adverse Reactions

  • Adjunctive therapy: In the adult placebo-controlled clinical trials, the most frequently seen adverse reaction with VIMPAT was dizziness (31% vs 8% placebo). Other common adverse reactions occurring in ≥10 percent of VIMPAT-treated patients, and greater than placebo, were headache, nausea, and diplopia.

  • Monotherapy: In the adult clinical trial, adverse reactions were generally similar to those observed and attributed to drug in adjunctive placebo-controlled trials, with the exception of insomnia (occurred at a higher rate of ≥2%).

  • Pediatric patients: Adverse reactions reported in clinical studies of pediatric patients 4 to less than 17 years of age were similar to those seen in adult patients.

  • Injection: In adult adjunctive therapy clinical trials, adverse reactions with intravenous administration generally were similar to those that occurred with the oral formulation, although intravenous administration was associated with local adverse reactions such as injection site pain or discomfort (2.5%), irritation (1%), and erythema (0.5%). When administering a loading dose, the incidence of CNS adverse reactions, such as dizziness, somnolence, and paresthesia may be higher with 15-minute administration than over a 30- to 60-minute period.

Dosing Considerations

VIMPAT injection is for intravenous and adult use only when oral administration is temporarily not feasible. The loading dose for adult patients should be administered with medical supervision considering the VIMPAT pharmacokinetics and increased incidence of CNS adverse reactions. The safety of VIMPAT injection and the use of a loading dose in pediatric patients have not been studied. Dosage adjustments are recommended for patients with mild or moderate hepatic impairment or severe renal impairment. Use in patients with severe hepatic impairment is not recommended. Perform dose titration with caution in all patients with renal and/or hepatic impairment.

VIMPAT is a Schedule V controlled substance.

Please see full Prescribing Information.

For more information on VIMPAT® contact 844-599-CARE (2273).

INDICATION

VIMPAT® is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of VIMPAT injection in pediatric patients has not been established, VIMPAT injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).

Press ReleaseUpdated Prescribing
Information
Modal Footer Content

SELECT IMPORTANT SAFETY INFORMATION

VIMPAT is associated with important warnings and precautions including suicidal behavior and ideation, dizziness and ataxia, cardiac rhythm and conduction abnormalities, syncope, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi-organ hypersensitivity.

In the adult monotherapy clinical trial, adverse reactions were generally similar to those observed and attributed to drug in adjunctive placebo-controlled trials, with the exception of insomnia (observed at a higher rate of ≥2%). In the adult adjunctive placebo-controlled trials, the most common adverse reactions (≥10% and greater than placebo) were dizziness, headache, nausea, and diplopia. Pediatric adverse reactions were similar to those seen in adult patients.

VIMPAT is a Schedule V controlled substance.

For more information, please see the updated full Prescribing Information and Medication Guide.

You are about to leave VIMPAT.com.

You are about to leave VIMPAT.com and are being redirected to an external website. UCB is not responsible for the content or services of that site or any further links from that site. Do you wish to continue?

Ok, continueNo, cancel